Fragile X Syndrome
-
New research on Fragile X syndrome reinforces importance of early detection
New insights into the long-lasting effects of Fragile X syndrome on connections in the brain during early development highlight the importance of early detection and treatment. Read MoreAug 25, 2017
-
Nobel in Chemistry reveals VU ties that bind
Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read MoreOct 18, 2012
-
New schizophrenia drug candidates entering prep for first-in-human testing
The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders. Read MoreDec 15, 2011
-
Researchers strive to refill drug discovery ‘pipeline’
Researchers at Vanderbilt University Medical Center have made substantial progress in developing potential new treatments for Parkinson’s disease, schizophrenia and fragile X syndrome, the most common genetic form of autism. Read MoreOct 3, 2011
-
Milestone in development of new treatment for ‘fragile X’
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism. Read MoreSep 15, 2011
-
Neuroscience drug discovery center opens at Vanderbilt
Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain. Read MoreMar 11, 2011